Updating results

Caesarean section (CG132)

This guideline covers when to offer caesarean section, procedural aspects of the operation and care after caesarean section. It aims to improve the consistency and quality of care for women who are considering a caesarean section or have had a caesarean section in the past and are now pregnant again.

Clinical guideline Published November 2011 Last updated September 2019

Twin and triplet pregnancy (NG137)

This guideline covers the care that should be offered to women with a twin or triplet pregnancy in addition to the routine care that is offered to all women during pregnancy. It aims to reduce the risk of complications and improve outcomes for women and their babies.

NICE guideline Published September 2019

Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults

Technology appraisal guidance Published September 2019

Benralizumab for treating severe eosinophilic asthma (TA565)

Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma (SEA; elevated levels of eosinophils in blood) in adults

Technology appraisal guidance Published March 2019 Last updated September 2019

The V.A.C. Veraflo Therapy system for infected wounds (MIB189)

Advice on the use of the V.A.C. Veraflo Therapy system for infected wounds to aid local decision making

Medtech innovation briefing Published September 2019

Wound care products (KTT14)

This document summarises the evidence base on wound care products . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants , including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published February 2016 Last updated September 2019

Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)

This document summarises the evidence base on the use of medicines in people with or at increased risk of acute kidney injury . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published February 2016 Last updated September 2019

Multimorbidity and polypharmacy (KTT18)

This document summarises the evidence base on multimorbidity and polypharmacy . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Shared decision making (KTT23)

This document summarises the evidence base on shared decision making . It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance .

Key therapeutic topic Published March 2019 Last updated September 2019

Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)

This document summarises the evidence base on suicide prevention: optimising medicines and reducing access to medicines as a means of suicide . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published March 2019 Last updated September 2019

Lipid-modifying drugs (KTT3)

This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)

This document summarises the evidence base on psychotropic medicines in people with learning disabilities whose behaviour challenges . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Safer insulin prescribing (KTT20)

This document summarises the evidence base on safer insulin prescribing . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Medicines optimisation in chronic pain (KTT21)

This document summarises the evidence base on medicines optimisation in chronic pain . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Chemotherapy dose standardisation (KTT22)

This document summarises the evidence base on chemotherapy dose standardisation . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published February 2018 Last updated September 2019

Asthma: medicines safety priorities (KTT5)

This document summarises the evidence base on asthma: medicines safety priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Hypnotics (KTT6)

This document summarises the evidence base on hypnotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Antipsychotics in people living with dementia (KTT7)

This document summarises the evidence base on antipsychotics in people living with dementia . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Antimicrobial stewardship: prescribing antibiotics (KTT9)

This document summarises the evidence base on antimicrobial stewardship: prescribing antibiotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)

This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Hypertension in adults: diagnosis and management (NG136)

This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.

NICE guideline Published August 2019

Type 2 diabetes in adults: management (NG28)

This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

NICE guideline Published December 2015 Last updated August 2019

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer that

Technology appraisal guidance Published August 2019

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published August 2019

Coexisting severe mental illness and substance misuse (QS188)

This quality standard covers the assessment, management and care provided for people aged 14 and over who have coexisting severe mental illness and substance misuse. It describes high-quality care in priority areas for improvement.

Quality standard Published August 2019

Patisiran for treating hereditary transthyretin amyloidosis (HST10)

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Highly specialised technologies guidance Published August 2019

Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms (IPG658)

Evidence-based recommendations on endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms in adults. This

Interventional procedures guidance Published August 2019

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive

Technology appraisal guidance Published August 2019

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Technology appraisal guidance Published August 2019

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced

Technology appraisal guidance Published August 2019

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

NICE guideline Published March 2018 Last updated August 2019

Alcohol interventions in secondary and further education (NG135)

This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.

NICE guideline Published August 2019

Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults

Technology appraisal guidance Published August 2019

PICO negative pressure wound dressings for closed surgical incisions (MTG43)

Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions

Medical technologies guidance Published May 2019 Last updated August 2019

Endo-SPONGE for colorectal anastomotic leakage (MIB188)

Advice on the use of Endo-SPONGE for colorectal anastomotic leakage to aid local decision making

Medtech innovation briefing Published August 2019

Preterm labour and birth (QS135)

This quality standard covers care for pregnant women who may be at risk of, or have symptoms and signs of, starting labour and giving birth early (preterm). It describes high-quality care in priority areas for improvement.

Quality standard Published October 2016 Last updated August 2019

Preterm labour and birth (NG25)

This guideline covers the care of women at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.

NICE guideline Published November 2015 Last updated August 2019

Patient experience in adult NHS services (QS15)

This quality standard covers improving the quality of the patient experience for people who use adult NHS services. It describes high-quality care in priority areas for improvement.

Quality standard Published February 2012 Last updated July 2019

Service user experience in adult mental health services (QS14)

This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.

Quality standard Published December 2011 Last updated July 2019

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

Technology appraisal guidance Published July 2019

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults

Technology appraisal guidance Published July 2019

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)

This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.

NICE guideline Published December 2018 Last updated July 2019

Generalised anxiety disorder and panic disorder in adults: management (CG113)

This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.

Clinical guideline Published January 2011 Last updated July 2019

End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0–17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

NICE guideline Published December 2016 Last updated July 2019

Learning disability: behaviour that challenges (QS101)

This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.

Quality standard Published October 2015 Last updated July 2019

Learning disability: care and support of people growing older (QS187)

This quality standard covers identifying, assessing and regularly reviewing the care and support needs of people with a learning disability as they grow older. People with a learning disability have many of the same age-related health and social care needs as other people, but this quality standard focuses on the specific challenges associated with their learning disability. It describes high-quality care in priority areas for improvement.

Quality standard Published July 2019

Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)

Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults

Interventional procedures guidance Published July 2019

Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids (IPG657)

Evidence-based recommendations on ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids in adults

Interventional procedures guidance Published July 2019

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia

Technology appraisal guidance Published July 2019